BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 12138654)

  • 1. [F-18 fluorodeoxyglucose positron emission tomography in malignant lymphoma].
    Mikosch P
    Wien Med Wochenschr; 2002; 152(11-12):269-75. PubMed ID: 12138654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography and lymphoma therapy.
    Golder W
    Onkologie; 2001 Oct; 24(5):496-8. PubMed ID: 11694779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
    Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
    Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
    Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of (18)F-FDG-PET/CT for staging and evaluation of therapeutic effect in patient with malignant lymphoma].
    Li F; Zhu HY; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):523-7. PubMed ID: 21518522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
    Liu Y
    Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
    Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Hegenbart U; Irngartinger G; Oberdorfer F; van Kaick G
    Radiologe; 1997 Jan; 37(1):74-80. PubMed ID: 9157479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET.
    Kasper B; Egerer G; Gronkowski M; Haufe S; Lehnert T; Eisenhut M; Mechtersheimer G; Ho AD; Haberkorn U
    Leuk Lymphoma; 2007 Apr; 48(4):746-53. PubMed ID: 17454633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET/computed tomography and lymphoma.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2013 Sep; 51(5):833-44. PubMed ID: 24010908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of FDG-PET for managing patients with malignant lymphoma: analysis of data from a single cancer center.
    Imataki O; Tamai Y; Yokoe K; Furukawa T; Kawakami K
    Intern Med; 2009; 48(17):1509-13. PubMed ID: 19721294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET and restaging of malignant lymphoma including residual masses and relapse.
    Reske SN
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S89-96. PubMed ID: 12748829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of PET/CT in lymphoma diagnostics].
    Afshar-Oromieh A; Kratochwil C; Haberkorn U; Giesel FL
    Radiologe; 2012 Apr; 52(4):338-46. PubMed ID: 22526115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography.
    Kostakoglu L; Goldsmith SJ
    Clin Lymphoma; 2000 Jun; 1(1):67-74; discussion 75-6. PubMed ID: 11707816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.